Reference 2018-495

REF:           2018-495

Subject:       Asthma Patients

 

Request:

  1. How many asthma patients aged 18 and over have been treated in the past 3 months [latest 3 months available],
  2. How many paediatric asthma treated patients [aged 6-17] have been treated?
  3. How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated?
  4. How many severe allergic asthma patients [severe persistent confirmed allergic IgE-mediated asthma OR severe persistent confirmed allergic eosinophilic asthma

Severe asthma patients treated with:

-Omalizumab [Xolair]

-Mepolizumab [Nucala]

-Reslizumab [Cinqaero]

-Benralizumab [Fasenra]

-Other [Please state]

  1. How many paediatric severe asthma patients have been treated with Xolair/omalizumab in the past 3 months?
  2. How many chronic spontaneous urticaria (CSU) patients have been treated with Xolair/omalizumab in the past 3 months?

 

 

Response:

Please find information attached.

2018-495 – FOI Request – Asthma Patients [11 kb] MS Excel